Mutual action of anticancer and antiparasitic drugs: are there any shared targets?

Zahra Dorosti1, Morteza Yousefi, Seyedeh Maryam Sharafi

  • 1Department of Parasitology & Mycology, Faculty of Medicine, Isfahan University of Medical sciences, Isfahan, Iran.

Insights

Parasites and cancers share common features, including antigens and drug targets. This review explores the mutual actions of anticancer and antiparasitic drugs, highlighting their shared therapeutic potential.

Area of Science:

  • Oncology
  • Parasitology
  • Pharmacology

Background:

  • Parasites and cancers exhibit shared biological characteristics.
  • Some parasites demonstrate an ability to inhibit tumor progression.
  • Common antigens, such as the Tn antigen, are found in both parasites and cancerous cells.

Purpose of the Study:

  • To review the mutual actions of anticancer and antiparasitic drugs.
  • To discuss the potential shared molecular targets for these drugs in both cancer and parasitic infections.

Main Methods:

  • Literature review of studies investigating anticancer and antiparasitic drug actions.
  • Analysis of research on common antigens and molecular pathways in parasites and cancers.

Main Results:

  • Evidence suggests a shared mechanism of action for certain anticancer and antiparasitic drugs.
  • Identification of common targets could lead to novel therapeutic strategies.

Conclusions:

  • The shared features between parasites and cancers suggest a basis for combined therapeutic approaches.
  • Further research into common drug targets may yield effective treatments for both conditions.

Related Concept Videos

Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
12.0K
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
90
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
74
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to...
104